Skip to content
Head to head

Adarx Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ADRX · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

ADRX -33.9%VRTX -2.1%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
ADRXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price12.79515.02
Change today-9.68%-1.08%
1-year return--+22.0%
Market cap$1.42B$130.58B
52-week range12.50 – 23.21412.27 – 568.67
Valuation
P/E (TTM)-13.9833.14
P/E percentile, own 5-yr range85th99th
P/B2.486.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.9715.32
Net profit (TTM)$-107.86M$3.88B
Revenue (TTM)--$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)+258.7%+11.8%
Gross margin--85.5%
Operating margin-1735.0%33.1%
Net margin-1434.1%30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership62.3%96.8%
Insider activity (12mo)10 buy / 0 sell28 buy / 22 sell
Short interest (% of float)1.8%1.9%
Analyst consensus100% buy (4)95% buy / 5% hold (21)
Analyst price target$35 (+174%)$624 (+21%)
StockVane view
StockVane Quant RatingC (0)C (68)
Company
Employees1006,400
Founded--1989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.